A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias

被引：0
|
作者：
Tara L. Lin
Laura F. Newell
Robert K. Stuart
Laura C. Michaelis
Eric Rubenstein
Helen S. Pentikis
Timothy Callahan
Donna Alvarez
Barry D. Liboiron
Lawrence D. Mayer
Qi Wang
Kamalika Banerjee
Arthur C. Louie
机构：
[1] University of Kansas Medical Center,Hollings Cancer Center
[2] Knight Cancer Institute,undefined
[3] Oregon Health and Science University,undefined
[4] Medical University of South Carolina,undefined
[5] Medical College of Wisconsin,undefined
[6] Oncology and Hematology Specialists,undefined
[7] Franciscan Health,undefined
[8] SAJE Consulting,undefined
[9] Biomedical Systems,undefined
[10] Celator/Jazz Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Acute myeloid leukemia; Acute lymphoblastic leukemia; Cardiac repolarization; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：163 / 173
页数：10
相关论文
共 50 条
  • [41] Phase IIB Randomized Study of CPX-351 Versus Conventional Cytarabine plus Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: An Interim Analysis
    Lancet, Jeffrey
    Feldman, Eric
    Kolitz, Jonathan
    Tallman, Martin
    Hogge, Donna E.
    Louie, Arthur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E28 - E28
  • [42] Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
    Kantarjian, H. M.
    Padmanabhan, S.
    Stock, W.
    Tallman, M. S.
    Curt, G. A.
    Li, J.
    Osmukhina, A.
    Wu, K.
    Huszar, D.
    Borthukar, G.
    Faderl, S.
    Garcia-Manero, G.
    Kadia, T.
    Sankhala, K.
    Odenike, O.
    Altman, J. K.
    Minden, M.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1107 - 1115
  • [43] Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML
    Uy, Geoffrey L.
    Newell, Laura F.
    Lin, Tara
    Goldberg, Stuart L.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Lancet, Jeffrey E.
    BLOOD, 2020, 136
  • [44] Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
    H. M. Kantarjian
    S. Padmanabhan
    W. Stock
    M. S. Tallman
    G. A. Curt
    J. Li
    A. Osmukhina
    K. Wu
    D. Huszar
    G. Borthukar
    S. Faderl
    G. Garcia-Manero
    T. Kadia
    K. Sankhala
    O. Odenike
    J. K. Altman
    M. Minden
    Investigational New Drugs, 2012, 30 : 1107 - 1115
  • [45] Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents
    Montalban-Bravo, Guillermo
    Jabbour, Elias J.
    Estrov, Zeev E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Chien, Kelly S.
    González, Graciela M. Nogueras
    Dong, Xiao Qin
    Fader, Stefan
    Schneider, Heather
    John, Rosmy B.
    Meyer, Meghan Anne
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138 : 3674 - +
  • [46] Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction
    Modi, NB
    Fox, NL
    Clow, FW
    Tanswell, P
    Cannon, CP
    Van de Werf, F
    Braunwald, E
    JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (05): : 508 - 515
  • [47] A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy
    Pontious, Corbin
    Garzon, Ramiro
    Blachly, James S.
    Blaser, Bradley Wayne
    Choe, Hannah
    Grieselhuber, Nicole R.
    Long, Meixiao
    Vasu, Sumithira
    Wall, Sarah A.
    Larkin, Karilyn T.
    Eisfeld, Ann-Kathrin
    Koenig, Kristin L.
    Sahasrabudhe, Kieran D.
    Sanchez-Petitto, Gabriela
    Saad, Ayman
    Bhatnagar, Bhavana
    Lyberger, Justin
    Borate, Uma M.
    Mims, Alice
    Jonas, Brian A.
    Behbehani, Gregory K.
    BLOOD, 2023, 142
  • [48] OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY
    Lancet, J. E.
    Rizzieri, D.
    Schiller, G. J.
    Stuart, R. K.
    Kolitz, J. E.
    Solomon, S. R.
    Newell, L. F.
    Erba, H.
    Uy, G. L.
    Ryan, R.
    Chiarella, M.
    Louie, A. C.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 214 - 215
  • [49] A Phase 2, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease
    Andemariam, Biree
    Sheehan, Vivien A.
    Hamza, Moayed
    Kelly, Kirsty
    Climax, John
    BLOOD, 2023, 142
  • [50] Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
    Rizzieri, David A.
    Schiller, Gary J.
    Solomon, Scott R.
    Newell, Laura F.
    Erba, Harry P.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    Lancet, Jeffrey E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S105 - S106
12345